ArticleJournal of autism and developmental disorders2021
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Véronique Crutel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.